<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734316</url>
  </required_header>
  <id_info>
    <org_study_id>Version 3 10/2/216</org_study_id>
    <nct_id>NCT02734316</nct_id>
  </id_info>
  <brief_title>Management of Direct Oral Anti-Coagulants (DOACs) for Gastrointestinal Endoscopy Procedures</brief_title>
  <official_title>Management of Direct Oral Anti-Coagulants (DOACs) for Gastrointestinal Endoscopy Procedures: an Observational, Cross-sectional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valduce Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valduce Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of Direct Oral Anti-Coagulants (DOACs) is expanding, but their proper management in&#xD;
      patients undergoing endoscopic procedures is still not completely clear. Current European&#xD;
      guidelines are based on weak data. This observational study aims to evaluate the&#xD;
      peri-endoscopic management of DOACs in clinical practice and the incidence of adverse events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This observational study is aimed at evaluating the peri-endoscopic management of DOACs in&#xD;
      patients undergoing elective gastrointestinal endoscopy procedures and the adverse events&#xD;
      (bleeding and thromboembolic events) associated with.&#xD;
&#xD;
      All consecutive patients undergoing elective procedures and providing informed consent will&#xD;
      be included.&#xD;
&#xD;
      Primary end-point:&#xD;
&#xD;
      incidence of major bleeding events according to International Society Thrombosis Haemostasis&#xD;
      (ISTH) criteria and clinically relevant non-major bleeding events occuring during the&#xD;
      endoscopy procedures or within 30 days, according to International Society Thrombosis&#xD;
      Haemostasis (ISTH) criteria in patients in which DOACs have been managed according to&#xD;
      European Society of Gastrointestinal Endoscopy (ESGE) guidelines&#xD;
&#xD;
      Secondary end points:&#xD;
&#xD;
        -  incidence of major bleeding and clinically relent non-major events in the overall&#xD;
           patient population&#xD;
&#xD;
        -  incidence of bleeding events in the overall patient population&#xD;
&#xD;
        -  incidence of thromboembolic events in the overall patient population and in patients in&#xD;
           which DOACs have been managed according to ESGE guidelines&#xD;
&#xD;
        -  compliance with ESGE guidelines&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>incidence of hemorrhagic events after endoscopic procedures</measure>
    <time_frame>12 months</time_frame>
    <description>incidence of hemorrhagic events after endoscopic procedures when the European Guidelines (ESGE) are followed</description>
  </primary_outcome>
  <enrollment type="Actual">531</enrollment>
  <condition>Anticoagulant Disorders</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>endoscopic procedure</intervention_name>
    <description>Evaluation of adverse events in patients on DOACs undergoing GI endoscopy</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients (both inpatients and outpatients) undergoing endoscopic procedures during DOACs&#xD;
        therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients (both inpatients and outpatients) undergoing endoscopic procedures during&#xD;
             DOACs therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inform consent not possible to obtain&#xD;
&#xD;
          -  not willing patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Valduce Hospital</name>
      <address>
        <city>Como</city>
        <zip>22100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>March 29, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Valduce Hospital</investigator_affiliation>
    <investigator_full_name>Franco Radaelli</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

